Information  X 
Enter a valid email address
  Print          More announcements

Friday 15 November, 2019

Bavarian Nordic A/S

Bavarian Nordic to Present at Jefferies 2019 London Healthcare Conference

Bavarian Nordic to Present at Jefferies 2019 London Healthcare Conference

COPENHAGEN, Denmark – November 15, 2019 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & CEO will provide a corporate presentation at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 3:20 pm GMT (4:20 pm CET).

A live and archived webcast of the presentation will be available at

Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to unlock the power of the immune system to improve public health with a focus on high unmet medical needs. In addition to our long-standing collaboration with the U.S. government on the development and supply of medical countermeasures, including the only FDA-approved, non-replicating smallpox vaccine, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable benefit-risk profile. For more information visit or follow us on Twitter @bavariannordic.

a d v e r t i s e m e n t